Abbott Laboratories stock: Abbott falls 5.02 percent. Abbott Laboratories stock trades at EUR 87.23

Published on 10/21/2026 at 17:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Adjusted earnings were USD 1.42 on October 21, 2026. Abbott Laboratories stock costs EUR 87.23 on October 21, 2026, down 5.02 percent versus Xetra close.

Third-quarter results and price move

Abbott reported USD 13.01 billion in third-quarter sales on October 21, 2026, up 14.50 percent year over year.
Adjusted earnings per share reached USD 1.42 in the third quarter ended September 30, 2026.
Abbott Laboratories stock costs EUR 87.23 at Lang & Schwarz on October 21, 2026 at 5:00 p.m. CEST, 5.02 percent below the Xetra close of October 20, 2026.

Bauhaus MEDTECH DIAGNOSTIK Abbott Laboratories US0028241000 — Abbott Laboratories US0028241000 Bauhaus-Poster MEDTECH DIAGNOSTIK Geometrie Primärfarben Rot Gelb Blau Schwarz Kreise Dreiecke, Illustration mit AI erstellt.

Abbott Laboratories (ISIN US0028241000) stock fell 5.02 percent against the Xetra close of October 20, 2026, as the euro quote reached EUR 87.23. On October 21, 2026, Fox 44 News carried Abbott's release reporting third-quarter sales of USD 13.01 billion, up 14.50 percent from the prior-year quarter. At Lang & Schwarz, the stock was trading at EUR 87.23 on October 21, 2026 at 5:00 p.m. CEST, down 5.02 percent from the Xetra close of EUR 91.84.

Sales growth hides a sharp earnings split

Abbott's third-quarter GAAP diluted earnings per share were USD 0.53, while adjusted diluted earnings per share reached USD 1.42. The adjusted figure increased from USD 1.30 in the third quarter of 2025, but GAAP earnings fell from USD 0.94 because the quarter included specified items such as intangible amortization and legal settlements, according to the release carried by Fox 44 News.

Diagnostics was the fastest-growing division, with third-quarter sales of USD 3.31 billion, up 46.70 percent year over year. Medical Devices generated USD 5.83 billion, up 6.90 percent, while Nutrition sales rose 5.10 percent to USD 2.26 billion.

Price position and valuation

The primary-market quote was USD 97.81 on October 21, 2026 at 11:01 a.m. ET, with a 52-week range of USD 81.97 to USD 132.03. Abbott's euro price therefore sits 19.32 percent above the lower end and 25.92 percent below the upper end when measured against the same-currency primary-market figures.

MarketBeat listed 28 analyst ratings as of October 20, 2026, with a Moderate Buy consensus and an average target of USD 118.88. The target stands 21.53 percent above the USD 97.81 primary-market quote, while the company carried a market capitalization of USD 169.2 billion.

Dividend date and guidance

Abbott declared a quarterly dividend of USD 0.63 per share on September 17, 2026, payable on November 16, 2026, to shareholders of record on October 15, 2026. The company also reaffirmed adjusted full-year 2026 earnings guidance of USD 5.50 to USD 5.55 per share and projected fourth-quarter adjusted earnings of USD 1.62 to USD 1.67 per share, according to the release carried by Fox 44 News.

The euro price moves lower

Abbott's current euro quotation is 5.02 percent below the prior Xetra close, while the latest quarter combines double-digit reported sales growth with lower GAAP earnings. The further course of trading is shown by the continuously updated real-time quote of Abbott Laboratories stock.